Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

about

C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.

P2860

Q53689778-92AEB64A-A214-4D79-BF2B-73A570F27CF0

P2860

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

Item

http://www.wikidata.org/entity/Q49508672

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

@en

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

@nl

type

Item

label

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

@en

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

@nl

prefLabel

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

@en

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

@nl

P1476

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer

@en

P2093

Beat Foerster

http://www.w3.org/2001/XMLSchema#string

Shahrokh F Shariat

http://www.w3.org/2001/XMLSchema#string

Shoji Kimura

http://www.w3.org/2001/XMLSchema#string

P2860

DNA Damage, Aging, and Cancer

Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Translational implications of tumor heterogeneity

Bladder Tumor Heterogeneity: The Impact on Clinical Treatment.

Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

The structural basis of XRCC1-mediated DNA repair

P304

1081-1089

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/TAU.2017.08.19

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mohammad Abufaraj

David D'Andrea

Andrea Mari

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29354495

http://www.w3.org/2001/XMLSchema#string

P932

5760393

http://www.w3.org/2001/XMLSchema#string

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

about

P2860

P2860

Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932